Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Seegene Inc    A096530   KR7096530001

SEEGENE INC

(A096530)
  Report
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Seegene : introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COVID-19 with dual internal controls

09/08/2020 | 08:04am EST

SEOUL, South Korea, Sept. 8, 2020 /CNW/ -- Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19 (S gene, RdRP gene and N gene).

Given the similarity in terms of symptoms between seasonal flu and SARS-CoV-2, multiplexing capability will be a critical consideration to accommodate high volume testing necessary for effective disease control in preparation for flu season during COVID-19 pandemic.

Seegene's assay incorporates its proprietary high multiplex chemistry technologies, maximizing sensitivity and specificity during PCR amplification and detection of multiple targets. Combined with its unique task target automated system and interpretation software solution, Seegene offers unparalleled capacity at the most competitive pricing available on the market.

The assay also includes dual targets for internal control (exogenous and endogenous, respectively) run in the same reaction tube, which allow verification of the whole test process as well as proper sampling.

"In preparation to the flu season during COVID-19 pandemic, differential diagnosis on common flu and COVID-19 will become important to allow different courses of action in treatment and quarantine. Our multiplex assay will be a powerful tool for labs to maintain the same high throughput and cost as testing COVID 19 alone, in comparison to running 4 different tests," said Dr. Jong-Yoon Chun, CEO of Seegene.

Over 60 million tests of COVID-19 were performed with Seegene's COVID-19 assay globally so far. Seegene is currently manufacturing 20 million tests a month, and it is ready to ramp up its production capacity by 2-3 times as required. At the same time, it continues its effort in expanding the applicable platforms to help laboratories choose the best-fit solution for additional test capacity.

The assay is currently validated with a wide range of extraction systems (Seegene STARlet, Seegene NIMBUS, Microlab STARlet IVD, Microlab NIMBUS, Seeprep32, KingFisher Flex, MagNA Pure 96, NucliSENS EasyMag, GeneAll Ribospin vRD Viral RNA/DNA Extraction Kit, QIAamp DSP Viral RNA Mini kit) and plans to expand further upon market demand. For PCR instruments, Bio-Rad CFX96 systems can be used.

Seegene also offers a comprehensive syndromic product portfolio on the same automated solution, including its well-established syndromic respiratory virus/bacteria panels which simultaneously detect 26 different targets.

About Seegene

Seegene (KQ : 096530) is a global pioneer in symptom-based in vitro molecular diagnostics focusing on advancing science to develop multiplex molecular technologies and to manufacture multiplex in vitro diagnostic devices and reagents. Seegene's core enabling power is the passion for wide spreading of multiplex molecular diagnostics to improve the quality of life and health of people. Using its innovative proprietary technologies, Seegene has been making considerable contributions to giving the most economic and clinic-friendly molecular diagnostic solutions for infectious diseases, genetics, pharmacogenetics, and oncology. For more information, please visit www.seegene.com or contact info@seegenetech.com.

Cision
View original content:http://www.prnewswire.com/news-releases/seegene-introduces-a-high-throughput-8-plex-test-for-flu-a-flu-b-rsv-and-covid-19-with-dual-internal-controls-301125437.html

SOURCE Seegene Inc.

© Canada Newswire, source Canada Newswire English

All news about SEEGENE INC
01/06SEEGENE : COVID-19 test with saliva sample collection feature now available in E..
AQ
2020SEEGENE : COVID-19/FluA,B/RSV test with extraction-free feature now available in..
AQ
2020Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
2020SEEGENE : introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COV..
AQ
2020SEEGENE : South Korean COVID-19 test kit maker Seegene posts second-quarter prof..
RE
2020Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
2020Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
2020Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
2020SEEGENE : Exports 10 million Corona Tests to Brazil
AQ
2020Hyundai's U.S. Actions in Response to Coronavirus (COVID-19)
AQ
More news
Financials
Sales 2020 1 039 B 0,94 B 0,94 B
Net income 2020 500 B 0,45 B 0,45 B
Net cash 2020 410 B 0,37 B 0,37 B
P/E ratio 2020 9,44x
Yield 2020 0,06%
Capitalization 4 676 B 4 241 M 4 241 M
EV / Sales 2020 4 500x
EV / Sales 2021 4 276x
Nbr of Employees 216
Free-Float 67,3%
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 330 560,00 KRW
Last Close Price 179 900,00 KRW
Spread / Highest target 139%
Spread / Average Target 83,7%
Spread / Lowest Target 48,4%
EPS Revisions
Managers and Directors
NameTitle
Jong-Yoon Chun Chief Executive Officer & Director
Jung-Yong Kim Director & Head-Finance
Kyung-Jun Chun Director
Hong-Il Yoon Independent Director
Jin-Soo Choi Director & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SEEGENE INC4 241
EXACT SCIENCES CORPORATION10.17%23 214
GUARDANT HEALTH, INC.23.60%15 925
INVITAE CORPORATION25.78%9 293
ADAPTIVE BIOTECHNOLOGIES CORPORATION10.08%8 903
BGI GENOMICS CO., LTD.13.25%8 900